Gregg Keaney, Senior Vice President of CMC and Product Development
Professional Overview
Gregg Keaney is a seasoned pharmaceutical executive with over 20 years of experience in drug discovery, product development, and strategic leadership. As the Senior Vice President of CMC (Chemistry, Manufacturing, and Controls) and Product Development at Rapport Therapeutics, he is responsible for driving the company's drug development pipeline and overseeing critical aspects of the product life cycle.
Experience Summary
Current Role
In his current position, Gregg is leading the CMC and product development efforts at Rapport Therapeutics, a biopharmaceutical company focused on developing innovative therapies for rare and difficult-to-treat diseases. He is responsible for guiding the company's drug candidates through the development process, ensuring compliance with regulatory requirements, and optimizing manufacturing processes to support clinical trials and commercial launch.
Career Progression
Prior to joining Rapport Therapeutics, Gregg held various leadership roles in drug discovery and product development at several prominent pharmaceutical and biotechnology companies. As the Senior Vice President of Drug Discovery and Product Development at Third Harmonic Bio, he played a crucial role in advancing the company's pipeline and overseeing the successful transition of multiple drug candidates from the research stage to clinical trials. Earlier in his career, Gregg served as the Vice President of Product Development at Cadent Therapeutics and Ataxion Therapeutics, where he made significant contributions to the advancement of novel therapies.
Academic Background
Gregg holds a Ph.D. in Chemistry from Yale University, where he specialized in medicinal chemistry and drug development. His academic achievements, including numerous publications in peer-reviewed journals, have earned him recognition within the scientific community.
Areas of Expertise
Gregg's expertise spans the entire drug development lifecycle, from early-stage research and preclinical studies to clinical development, manufacturing, and regulatory affairs. He has deep knowledge of CMC processes, including formulation development, analytical method validation, and scale-up manufacturing. Additionally, Gregg's strong background in project management and cross-functional collaboration enables him to effectively lead multidisciplinary teams and drive the successful completion of complex drug development projects.
Professional Impact
Throughout his career, Gregg has made significant contributions to the advancement of therapeutic solutions for patients with rare and complex diseases. His leadership and strategic vision have been instrumental in the successful development and regulatory approval of several innovative drug candidates. Gregg's industry contributions and technical expertise have earned him a reputation as a respected and influential leader in the pharmaceutical industry.
Conclusion
With his extensive experience, technical expertise, and proven track record of success, Gregg Keaney is well-positioned to drive the continued growth and development of Rapport Therapeutics' promising pipeline of novel therapies. His commitment to advancing the field of pharmaceutical research and development, combined with his strong leadership skills, make him a valuable asset to the company and the broader industry.
